The Mutual UFO Network (MUFON) announced changes today to its board of directors as longtime board member Tom Deuley tendered his resignation.
Deuley will officially retire from the board at the 2014 MUFON Symposium in Cherry Hill, NJ. Deuley has been following the UFO business since 1954. He joined MUFON in the fall of 1976 and has been active ever since. Besides being a former State Director and a member of the MUFON Board for over 25 years, he has also been actively involved in the Fund for UFO Research, managed the AMP project for the UFO Research Coalition, and has been a serious spokesman for using the scientific approach in solving the UFO enigma.
Now in full retirement, Deuley has a strong desire to get back to his roots in the arts and have the time to enjoy the creative side of his life in retirement.
"Please join me in congratulating Tom on his many contributions to MUFON," Executive Director Jan C. Harzan said today. "Tom has had a truly outstanding career in Ufology over the past five decades."
Stepping into the new board position is Hollywood Producer Anthony J. Cataldo, who has made over a dozen feature films including “Replicant” (2001), “Shortcut to Happiness” (2003) and “Escape to Grizzly Mountain” (2004), and has worked with actors/directors such as Gus Van Sant, Anthony Hopkins, Christopher Walken, Alec Baldwin, Martin Landau, Jean Claude Van Damm, to name a few.
Cataldo was Chairman and CEO of Miracle Entertainment (formerly Cannon Films) for four years. He is currently working on his next film, “701 The Movie.”
Other positions include: Chairman and Chief Executive Officer and Director. Mr. Cataldo served as Chief Executive Officer and Chairman of VoIP, Inc. from September 2006 through April 2008. During the past five years, he has served as non-executive chairman of the board of directors of BrandPartners Group, Inc., a provider of integrated products and services dedicated to providing financial services and traditional retail clients with turn-key environmental solutions from October 2003 through August 2006. He also served as non-executive co-chairman of the board of MultiCell Technologies, Inc., a supplier of functional, non-tumorigenic immortalized human hepatocytes from February 2005 through July 2006; and executive chairman of Calypte Biomedical Corporation, a publicly traded biotechnology company, involved in the development and sale of urine based HIV-1 screening tests from May 2002 through November 2004.
Prior to that, Mr. Cataldo served as the Chief Executive Officer and Chairman of the Board of Directors of Miracle Entertainment, Inc., a Canadian film production company, from May 1999 through May 2002, where he was the executive producer or producer of several motion pictures.
From August 1995 to December 1998, Mr. Cataldo served as President and Chairman of the Board of Senetek, PLC, a publicly traded biotechnology company involved in age-related therapies. Most recently, From February 2011 to June 2013, Mr. Cataldo served as Chairman and CEO/ Founder of Genesis Biopharma, Inc. Mr. Cataldo created Genesis Biopharma with the inclusion of assets purchased from the National Cancer Institute (NIH) for their novel treatment of Stage Four Cancer treatment for melanoma.